Convalescent plasma therapy and long-term SARS-COV-2 antiviral immune response in a prospective cohort of patients with COVID-19
During the SARS-CoV-2 pandemic, the use of convalescent plasma (CP) in high-risk patients was proposed and widely implemented in several countries as a potential COVID-19 therapy. Nonetheless, CP therapy’s impact on immune response is nowadays poorly understood, including the correlation between IgG...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2025-01-01
|
| Ráidu: | Current Research in Microbial Sciences |
| Fáttát: | |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2666517425001014 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
